Phaseline

Companies › R3 Stem Cell

R3 Stem Cell: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Umbilical Cord Wharton's Jelly Allograft
Allograft tissue containing mesenchymal stem cells and extracellular matrix components
–Phase 1Low Back PainMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06361485Umbilical Cord Wharton's Jelly AllograftPhase 1Low Back PainImmunologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.